Rofecoxib
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314273

CAS#: 162011-90-7

Description: Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that has now been withdrawn over safety concerns. Rofecoxib exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of rofecoxib is believed to be due to inhibition of prostaglandin synthesis, via inhibition of cyclooxygenase-2 (COX-2). At therapeutic concentrations in humans, rofecoxib does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. Studies to elucidate the mechanism of action of fofecoxib in the acute treatment of migraine have not been conducted.


Price and Availability

Size
Price

100mg
USD 250
1g
USD 1250
10g
USD 4850
Size
Price

250mg
USD 450
2g
USD 1950
20g
USD 7450
Size
Price

500mg
USD 750
5g
USD 2950

Rofecoxib, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 314273
Name: Rofecoxib
CAS#: 162011-90-7
Chemical Formula: C17H14O4S
Exact Mass: 314.06128
Molecular Weight: 314.36
Elemental Analysis: C, 64.95; H, 4.49; O, 20.36; S, 10.20


Synonym: MK966; MK966; MK 966; MK0966; MK0966; MK 0966; Rofecoxib; brand name: Vioxx; Ceoxx; Ceeoxx.

IUPAC/Chemical Name: 4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

InChi Key: RZJQGNCSTQAWON-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

SMILES Code: O=C1C(C2=CC=CC=C2)=C(C3=CC=C(S(=O)(C)=O)C=C3)CO1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

 1: Rahme E, Roussy JP, Lafrance JP, Nedjar H, Morin S. Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib? J Rheumatol. 2011 Feb;38(2):195-202. doi: 10.3899/jrheum.100332. Epub 2010 Nov 15. Review. PubMed PMID: 21078717.

2: Bulley S, Derry S, Moore RA, McQuay HJ. Single dose oral rofecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004604. doi: 10.1002/14651858.CD004604.pub3. Review. PubMed PMID: 19821329; PubMed Central PMCID: PMC4171390.

3: Jaksch W, Dejaco C, Schirmer M. 4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int. 2008 Oct;28(12):1187-95. doi: 10.1007/s00296-008-0650-4. Epub 2008 Jul 29. Review. PubMed PMID: 18663451.

4: Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review. PubMed PMID: 18405470.

5: Mason RP, Walter MF, Day CA, Jacob RF. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. Subcell Biochem. 2007;42:175-90. Review. PubMed PMID: 17612051.

6: Burnier M. The safety of rofecoxib. Expert Opin Drug Saf. 2005 May;4(3):491-9. Review. PubMed PMID: 15934855.

7: Krymchantowski AV, Bigal ME. Rofecoxib in migraine. Expert Rev Neurother. 2005 Jan;5(1):55-61. Review. PubMed PMID: 15853474.

8: Marshall LL. Angioedema associated with aspirin and rofecoxib. Ann Pharmacother. 2005 May;39(5):944-8. Epub 2005 Apr 5. Review. PubMed PMID: 15811906.

9: Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral rofecoxib for postoperative pain. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004604. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004604. PubMed PMID: 15674955.

10: Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review. PubMed PMID: 15674912.

11: Garner SE, Fidan DD, Frankish R, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005115. Review. PubMed PMID: 15654705.

12: Scheen AJ. [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. Rev Med Liege. 2004 Oct;59(10):565-9. Review. French. PubMed PMID: 15623076.

13: Lizán Tudela L, Magaz Marqués S, Varela Moreno C, Riesgo Bucher Y. [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. Aten Primaria. 2004 Dec;34(10):534-40. Review. Spanish. PubMed PMID: 15607056.

14: Szalat A, Krasilnikov I, Bloch A, Meir K, Rubinger D, Mevorach D. Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. Arthritis Rheum. 2004 Aug 15;51(4):670-3. Review. PubMed PMID: 15334443.

15: Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral rofecoxib for postoperative pain. Cochrane Database Syst Rev. 2004;(1):CD004604. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD004604. PubMed PMID: 14974074.

16: Schmidt H, Woodcock BG, Geisslinger G. Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. Drug Saf. 2004;27(3):185-96. Review. PubMed PMID: 14756580.

17: Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. Review. PubMed PMID: 14658947.

18: Coulter DM, Clark DW, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ. 2003 Nov 22;327(7425):1214-5. Review. PubMed PMID: 14630760; PubMed Central PMCID: PMC274063.

19: Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003 Oct;146(4):591-604. Review. PubMed PMID: 14564311.

20: Ahuja N, Singh A, Singh B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol. 2003 Jul;55(7):859-94. Review. PubMed PMID: 12906745.